Authors

  • Phani Chandra Barla
    Principal Quality Engineer, Senseonics Inc 20451 Seneca Meadows Parkway, Germantown, MD 20876-7005
  • Dr. Laina Karthikeyan
    Professor, Department of Biological Sciences, New York City College of Technology, 285 Jay St, Brooklyn, NY 11201

DOI:

https://doi.org/10.37547/tajet/Volume06Issue06-04

Keywords:

Quality Assurance Medical Device Manufacturing Artificial Intelligence

Abstract

The production process for medical devices must precisely follow quality assurance (QA) procedures to comply with the sector's stringent regulatory requirements. Although conventional QA procedures are generally effective, they can be time-consuming and resource-intensive, which can lead to problems and increased costs. With its unprecedented potential for increased productivity, accuracy, and scalability, Artificial Intelligence (AI) has revolutionized quality assurance (QA) approaches across industries since its inception. In this study, we look at how artificial intelligence (AI) could improve medical device quality assurance procedures. Artificial intelligence (AI) methods such as computer vision, machine learning, and natural language processing can automate and optimize critical QA operations, allowing manufacturers to expedite production workflows, while improving product quality. Systems powered by artificial intelligence can sift through mountains of data in search of irregularities, defects, and faults, and they can do it in real-time. This lessens the likelihood of non-compliance problems and enables proactive response. Furthermore, QA systems driven by AI offer the ability to learn and adapt, which allows them to continuously improve performance by analyzing input and meeting evolving regulatory requirements.


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF ENGINEERING AND TECHNOLOGY (ISSN

2689-0984)

VOLUME 06 ISSUE06

24

https://www.theamericanjournals.com/index.php/tajet

PUBLISHED DATE: - 26-06-2024

DOI: -

https://doi.org/10.37547/tajet/Volume06Issue06-04

PAGE NO.: - 24-31

HARNESSING ARTIFICIAL INTELLIGENCE FOR REAL-

TIME QUALITY ASSURANCE IN MEDICAL DEVICE

MANUFACTURING

Phani Chandra Barla

Principal Quality Engineer, Senseonics Inc 20451 Seneca Meadows Parkway, Germantown, MD

20876-7005

Dr. Laina Karthikeyan

Professor, Department of Biological Sciences, New York City College of Technology, 285 Jay St,

Brooklyn, NY 11201

INTRODUCTION

In the field of medical device manufacturing,

ensuring the quality and reliability of the products

is of utmost importance to safeguard patient safety.
Defects or malfunctions in medical devices can

have severe consequences, ranging from
compromised patient care to potential harm or

even loss of life. Therefore, the detection of defects

during the manufacturing process is critical to
prevent faulty devices from reaching the market.

Traditional methods of defect detection in medical

device manufacturing often rely on manual

inspection by human operators. While these
methods have proven effective to some extent, they

are inherently limited by human subjectivity,
fatigue, and the potential for human error.

Moreover, the complexity and intricacy of modern
medical devices make it increasingly challenging

for human inspectors to identify subtle defects or
anomalies. To overcome these limitations and

enhance defect detection capabilities, artificial
intelligence (AI) has emerged as a transformative

RESEARCH ARTICLE

Open Access

Abstract


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF ENGINEERING AND TECHNOLOGY (ISSN

2689-0984)

VOLUME 06 ISSUE06

25

https://www.theamericanjournals.com/index.php/tajet

technology in the manufacturing industry. AI-

powered defect detection systems leverage
advanced

algorithms

and

computational

techniques to analyze large volumes of data and
automatically identify and classify defects in

medical devices. The application of AI in defect
detection offers several advantages over

traditional approaches. AI algorithms can process
vast amounts of data with speed and precision,

enabling the detection of even the most subtle
defects that may go unnoticed by human

inspectors.

Additionally,

AI

systems can

continuously learn and improve their defect
recognition abilities through machine learning

techniques, ensuring higher accuracy and
adaptability over time.

In today’s rapidly evolving pharmaceutical and

medical device industries, maintaining high
standards of quality assurance is paramount. As

technology continues to advance, innovative
solutions such as artificial intelligence (AI) and

automation are revolutionizing the validation

process. The world is being changed at a dizzying
rate by artificial intelligence (AI). Artificial

intelligence (AI) has entered many facets of our
daily lives, from self-driving vehicles to virtual

assistants. The quality field is one area where AI
has the potential to make a big difference. Utilizing

AI for quality management allows firms to detect
and resolve quality issues early on, guaranteeing

that products and services live up to customer
expectations.
Artificial intelligence (AI) is a subfield of computer

science that focuses on the application of

sophisticated algorithms and processing abilities
to the problem of extracting useful insights from

large datasets, with a particular emphasis on the
context of the fourth industrial revolution. With the

advent of the Internet of Things (IoT), production
will see a marked improvement in efficiency,

quality, management ease, and transparency. How?
By utilizing Industry 4.0-based smart factories that

integrate physical and cybertechnologies. One of
the most important ways to make factory

automation systems smarter is to use sensors and
AI [3,4].
In this new era of Digital Transformation, quality is

no longer about raw data, but the way we process

the data and the insights we extract from it. There
is no doubt that the combination of Artificial

Intelligence (AI) and Quality Management is not
just a dream but is already reshaping the way we

do business today. It is a game-changer.
The expansion of numerous sectors and the

improvement of national economies are highly
dependent on the development and improvement

of sensor technology, particularly as it pertains to
Industry 4.0. To collect data and put it to good use,

manufacturing organizations and supply chains
need access to modern, inexpensive sensor

technology. The most common kinds of sensors
include those that measure location, flow,

temperature, pressure, and force. Motorsport,
healthcare, manufacturing, the military, and

agriculture are just a few of the many industries
that depend on them frequently. Improving

productivity through the use of automation is the
goal of Industry 4.0 [5,6]. Recent advances in

healthcare using AI methods have sparked a heated

debate about whether AI doctors will one day
replace human doctors [7,8].

LITERATURE REVIEW

The possibility of computers fully replacing human

doctors is quite improbable for the near future.

However, AI might substantially help doctors make
better clinical decisions. A few medical fields, like

radiology, may even be able to do away with human
judgment altogether thanks to AI [9,10]. The recent

successful deployment of AI in healthcare has been
made possible by the fast improvement of big data

analysis techniques and the increasing accessibility
of healthcare data. In order to answer important

clinical issues and extract useful information from
the massive amounts of data, sophisticated AI

algorithms are being used. With this information,
clinical decision-making can be improved [11,12].

The ever-evolving manufacturing, medical device,
pharmaceutical, and food and beverage industries

must maintain the highest standards of quality at

all times [13,14]. As a game-changing technology,
artificial intelligence (AI) is revolutionizing the

quality management system (QMS) industry.
Quality Control (QC) and Quality Assurance (QA)

are being transformed by technology.


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF ENGINEERING AND TECHNOLOGY (ISSN

2689-0984)

VOLUME 06 ISSUE06

26

https://www.theamericanjournals.com/index.php/tajet

To ensure that products and services meet or

exceed customer expectations and established
standards, quality management is essential in

many sectors [15]. As technology advances, the
integration of artificial intelligence (AI) is

revolutionizing traditional business practices. With
the introduction of AI, quality assurance (QA) has

undergone a radical transformation [16]. It would
be foolish to ignore the substantial benefit that AI

provides in terms of streamlining and improving
testing procedures. To gain a substantial

competitive edge, businesses need to know how to

incorporate artificial intelligence (AI) into their
testing procedures. Quality assurance (QA) teams

may improve their efficiency by moving away from
manual testing and toward more advanced

autonomous testing technologies, which are
discussed in this article, which offer a thorough

study of AI's possibilities in QA [17].

Intelligent 3D printing of personalized

medicines

There has been a digital revolution in the past

quarter of a century, beginning with the

introduction of wireless internet and continuing
with the ubiquitous usage of smartphones around

the world, cloud computing, and social media.
These revolutionary inventions were initially

designed and used by intelligent humans.

The modern catalog of pharmaceutical 3D

printing technologies

Printing nearly every kind of medication is now

possible because to pharmaceutical 3DP, which is a

combination of separate technologies. To grasp the
potential of AI in pharmaceutical 3DP, one must

first acknowledge the diversity and difficulties of
the available approaches, as well as their benefits

and drawbacks when applied to specific

medications and excipients.

Alternative

optimization

techniques

to

machine learning in 3D printing

The intricacy of pharmaceutical 3DP means that

developing new drugs through trial and error is not

only inefficient but also runs the risk of producing
subpar results. Decisions about printing method

and formulation components are examples of
macro-level choices that must be considered while

creating a new 3DP drug.

METHODOLOGY
Data-Driven Decision-Making

Quality assurance technologies powered by AI can

instantly sift through mountains of data, revealing

patterns and trends that can guide business
choices. As a result, quality management becomes

more proactive, which speeds up the process of
finding and fixing problems. Utilizing AI-powered

quality

assurance

technologies,

a

car

manufacturing company, for instance, can examine

real-time data from multiple sources, including

production lines, customer feedback, and historical
records. The business may improve its quality

management strategy and make better judgments
by seeing patterns, insights, and trends and acting

swiftly to resolve any problems that may arise.

Automated Quality Control:

Businesses may automate quality control

operations with the help of AI algorithms, which
reduces human error and increases productivity.

This guarantees a higher degree of accuracy in
finding defects and inconsistencies in goods and

services while simultaneously saving time and
resources. Using AI algorithms, a pharmaceutical

corporation may automate the production process
inspection of pills and capsules with a precision of

99.999%. To provide safer and more dependable
pharmaceuticals, the corporation must decrease

human error and increase efficiency to guarantee a
better degree of precision in spotting defects and

inconsistencies.

Predictive Quality Management:

Artificial intelligence (AI) applied to quality

management can look at past data and find trends
that could cause difficulties in the future. Ensuring

a constant level of quality and boosting client

happiness are both made possible when
organizations handle potential issues before they

become significant. Applying AI to quality control
at a food processing plant, for instance, could help

spot trends in past data that could indicate
impending problems with product quality. With

this kind of planning, the plant can head off
problems before they even start, which keeps


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF ENGINEERING AND TECHNOLOGY (ISSN

2689-0984)

VOLUME 06 ISSUE06

27

https://www.theamericanjournals.com/index.php/tajet

quality consistent and makes customers satisfied.

AI in Quality Management: A Case Study

With the help of an AI-driven quality management

system, a prominent car manufacturer was able to

raise the bar on product excellence. Data from
production lines, suppliers, and customer feedback

were all inputted into the system by use of artificial
intelligence algorithms. Potential flaws and quality

process aberrations were detected by the system,
allowing for the implementation of preventive

steps. Manufacturers can enhance their quality
control procedures with the help of the system's

real-time monitoring and continuous improvement
features. Manufacturers saw a 30% drop in quality-

related expenses and a 20% uptick in happy
customers because of it.

Manufacturing Excellence with AI:

Maintaining a high level of consistency and

accuracy is critical in the manufacturing industry.

When it comes to improving and optimizing each
stage of the production process, AI is important.

The next generation of quality management

systems, driven by artificial intelligence, can help
manufacturers achieve quality control like never

before. Computer programs powered by artificial
intelligence can instantly sift through mountains of

data in search of trends and outliers that a human
eye could miss. Early defect discovery, less waste,

and higher overall product quality are all results of
its pattern recognition and anomaly spotting

capabilities.
On top of that, cloud-based quality management

systems make it easy for diverse production units
and regions to work together and share data. This

guarantees that no matter how far apart locations
are, quality requirements will always be satisfied.

The end product is an AI-powered, highly
integrated manufacturing environment, that takes

quality to new levels.

Medical Devices: A Leap Forward in Precision

Accuracy is of the utmost importance in the

medical devices sector. Artificial intelligence is
changing the medical device manufacturing

industry with its large dataset processing and
learning capabilities. Quality management systems

powered by AI guarantee that all stages, from

design and prototyping to production and post-
market surveillance, are carried out to the highest

standards of quality.
Medical device producers must adhere closely to

the FDA's strict rules. With the help of AI, not only

are these regulatory standards more easily met, but

the clearance procedure is also faster and more
accurate. Artificial intelligence (AI) allows medical

device companies to speed up product
development without sacrificing quality or safety.

Pharma

and

Lifesciences:

Accelerating

Innovation and Compliance

AI is revolutionizing the pharmaceutical and life

sciences industry, which is characterized by a close
relationship between innovation and compliance.

There are a lot of moving parts and strict quality
controls involved in creating and releasing new

medications to the market. AI-powered quality
management systems streamline this process by

taking over mundane, repetitive jobs, freeing up
researchers and scientists to concentrate on new

ideas. Furthermore, AI ensures compliance in an
area where following FDA standards is absolutely

essential. The likelihood of non-compliance issues
is greatly reduced since it guarantees that every

phase of drug research and manufacture conforms

with regulatory criteria. The approval procedure is
accelerated and pharmaceutical companies'

reputations are protected.

Food and Beverages: Ensuring Safety and

Consistency

In order to ensure the safety and happiness of

consumers, the food and beverage business must

maintain consistent quality. Precision and real-
time monitoring are essential in this sector, and AI

offers both to QMS. Using AI, we can guarantee that
every stage, from sourcing raw materials to

packaging and distribution, is done to the highest
quality standards.
With the use of cloud-based quality management

system solutions, businesses can monitor the

whereabouts of all their products and ingredients
as they move through the supply chain. In the event

of a quality issue, this traceability is vital for
avoiding extensive recalls and protecting the


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF ENGINEERING AND TECHNOLOGY (ISSN

2689-0984)

VOLUME 06 ISSUE06

28

https://www.theamericanjournals.com/index.php/tajet

reputation of the brand.
The application of AI in QA also includes predictive

maintenance for production machinery, which
lessens the likelihood of unanticipated failures that

can lower product quality. This preventative
method improves operating efficiency and

guarantees product uniformity.

The Power of Cloud-QMS

The AI-driven quality management system (QMS)

cloud revolution is supported by cloud-based
solutions. With this unified platform, stakeholders

can save, analyze, and collaborate on data in real-

time, regardless of their location. Businesses with a
worldwide supply chain or numerous production

facilities will benefit greatly from this degree of
interconnection.
Data security and integrity are guaranteed by the

cloud-QMS strategy, which also improves
cooperation. Companies may rest certain that their

critical quality data is safeguarded from breaches
or loss, thanks to strong encryption and backup

measures. Because of this, both consumers and

regulatory agencies have more faith in the sector.

RESULTS AND DISCUSSION

The rapid identification of respiratory pathogens,

such as parainfluenza virus, influenza virus,

respiratory syncytial virus and/or adenovirus,

especially during a winter period, is of great
importance for the prevention of nosocomial

spread, for monitoring infected patients, and for
improved clinical management. Rightfully so, there

is added pressure for clinical laboratories to be
able to provide rapid and sensitive applications for

the testing of these respiratory pathogens,
particularly for immunocompromised individuals,

the young and the elderly.
A rapid diagnostic test should be able to provide

the clinician with a result within a short time frame,
to allow for prompt and appropriate therapeutic

action. Reverse transcriptase-PCR assay (RT-PCR)
is the gold standard for diagnosing viral infections

including the COVID-19 because it can identify the

infectious agent, severe acute respiratory

syndrome coronavirus 2 (SARS-CoV-2). An unusual
need for polymerase chain reaction (PCR) testing

in diagnostic laboratories across the globe was
noted as COVID-19 rapidly propagated from

person to person during the pandemic. For the
purpose of reducing the workload of healthcare

and laboratory professionals, several AI-aided
detection models have been created to quickly and

accurately diagnose SARS-CoV-2 using RT-PCR. A
deep learning model called qPCRdeepNet was

proposed by Alouani et al. It uses a deep

convolutional neural network to analyze
fluorescence readings taken during COVID-19 RT-

PCR.
The goal of the model is to increase test specificity

and detect false positive results. Along with this,

Lee et al. created a deep learning model using the
long-term short memory (LSTM) technique. This

model was fed raw data of fluorescence levels from
each of the 40 RT-PCR test cycles.
In their analysis of patients' clinical data, blood test

findings, and chest CT imaging data, the authors

found that RT-PCR diagnosis time was decreased.
Similarly, the authors automatically classified RT-

PCR data as positive, weak-positive, negative, or re-
run using an AI-based detection and classification

system for COVID-19 RT-PCR diagnosis that
utilized fluorescence data and amplification curves.

Additionally, Villarreal-González et al. classified
4230 RT-PCR curves from patient data into

positive, early, no, and abnormal amplifications

using various ML models. The top model achieved
rapid diagnosis while reducing false positives by

detecting atypical profiles in PCR curves caused by
contamination or artifacts. It has also been utilized

to detect SARS-CoV-2 variations.
During the pandemic, researchers used RT-PCR

data to train an ML algorithm that relies on the

number of cycles (cycle threshold, Ct). The
technique's proponents posited that different virus

variants can be detected by identifying patterns in


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF ENGINEERING AND TECHNOLOGY (ISSN

2689-0984)

VOLUME 06 ISSUE06

29

https://www.theamericanjournals.com/index.php/tajet

Figure 1. Number of approved (USA) and CE-marked (Europe) AI/ML-based medical devices

between 2015 and 2019

the Ct values of PCR-positive samples. The use of

laser-scribed graphene (LSG) sensors in
conjunction with a biosensing platform for gold

nanoparticles (AuNPs) was also employed by
Beduk et al. to detect SARS-CoV-2 variations using

a Dense Neural Network (DNN) algorithm.
Streamlining the interpretation of RT-PCR tests

and reducing the need for human intervention in

laboratory practice have both been greatly aided

by the AI-driven SARS-CoV-2 diagnosis. From 2015
to 2019, figure 1 also displayed the number of

AI/ML-based medical devices that were approved
in the US and CE-marked in Europe. See the

healthcare industry's use of AI from 2021

2030 in

Figure 2. Several aspects of healthcare operations

can greatly benefit from the use of AI, such as the
management of chronic diseases, the automation

and optimization of workflows, the early detection
of risks, and the improvement of patient care.


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF ENGINEERING AND TECHNOLOGY (ISSN

2689-0984)

VOLUME 06 ISSUE06

30

https://www.theamericanjournals.com/index.php/tajet

Figure 2. AI in healthcare from 2021 to 2030

CONCLUSIONS

Applications of artificial intelligence are inevitably

going to become a part of modern healthcare.

These applications have a high potential to assist
caretakers and decision-makers in the areas of

laboratory and imaging diagnosis, antimicrobial
stewardship,

discovery

of

antimicrobials,

microbiome-based translational interventions,
infectious disease surveillance, prediction, and

prevention. The widespread digitization of medical

records, which has made data more accessible, as
well as the advancements in computer power have

been extremely helpful and will continue to be
essential for the research and development that

will take place in the sector in the future. Despite
the fact that artificial intelligence is usually

considered to be a danger to "common"
employment, its incorporation into healthcare

should be viewed as an opportunity for enhanced

patient care and infection management, higher
survival, improved staffing and resource allocation,

and decreased costs in healthcare systems.

REFERENCES

1.

Harrer S, et al. Artificial intelligence for clinical

trial design. Trends Pharmacol. Sci. 2019;
40:577

591. doi: 10.1016/j.tips. 2019.05.005.

[PubMed] [CrossRef] [Google Scholar].

2.

Li BT, et al. Reimagining patient-centric cancer

clinical trials: a multi-stakeholder international
coalition. Nat. Med. 2022; 28:620

626. doi:

10.1038/s41591-022-01775-6.

[PubMed]

[CrossRef] [Google Scholar]

3.

Dagenais S, et al. Use of real-world evidence to

drive drug development strategy and inform

clinical trial design. Clin. Pharmacol. Ther.
2022; 111:77

89. doi: 10.1002/ cpt.2480.

[PMC free article]


background image

THE USA JOURNALS

THE AMERICAN JOURNAL OF ENGINEERING AND TECHNOLOGY (ISSN

2689-0984)

VOLUME 06 ISSUE06

31

https://www.theamericanjournals.com/index.php/tajet

4.

Liu R, et al. Evaluating eligibility criteria of

oncology trials using real-world data and AI.
Nature. 2021; 592:629

633.

5.

Ithapu VK, et al. Imaging-based enrichment

criteria using deep learning algorithms for
efficient clinical trials in mild cognitive

impairment. Alzheimers Dement. 2015;

11:1489

1499. doi: 10.1016/j.jalz. 2015.01.10.

[PMC free article] [PubMed] [CrossRef] [Google

Scholar]

6.

Ezzati A, et al. Machine learning predictive

models can improve efficacy of clinical trials for

Alzheimer’s disease. J. Alzheimers Dis. 2020;

74:55

63. doi: 10.3233/JAD-190822. [PMC

free article] [PubMed] [CrossRef] [Google
Scholar]

7.

Mohan A, et al. A machine-learning derived

Huntington’s disease progression model:

insights for clinical trial design. Mov.

8.

de Jong J, et al. Towards realizing the vision of

precision medicine: AI based prediction of

clinical drug response. Brain. 2021; 144:1738

1750. doi: 10.1093/brain/awab-108. [PMC
free article] [PubMed] [CrossRef] [Google

Scholar].

9.

Hassanzadeh H, et al. Matching patients to

clinical trials using semantically enriched.

10.

Alexander M, et al. Evaluation of an artificial

intelligence clinical trial matching system in

Australian lung cancer patients. JAMIA.

11.

Haddad T, et al. Accuracy of an artificial

intelligence system for cancer clinical trial

eligibility screening: retrospective Pilot Study.
JMIR Med. Inform. 2021;9:e27767.

12.

Beck JT, et al. Artificial intelligence tool for

optimizing eligibility screening for clinical
trials in a large community cancer center. JCO

Clin. Cancer Inform. 2020; 4:50

59. doi:

10.1200/CCI.19.00079. [PubMed] [CrossRef]

[Google Scholar]

13.

Kim J, et al. Review of the performance metrics

for natural language systems for clinical trials
matching. Stud. Health Technol. Inform. 2022;

290:641

644. [PubMed] [Google Scholar]

14.

Unlearn works with pharma sponsors, biotech

companies,

and

academic

institutions.

https://www.businesswire
.com/news/home/20220419005354/en

15.

European Medicines Agency releases for public

consultation its draft policy on the publication

and access to clinical-trial.

16.

Abramson A, et al. A flexible electronic strain

sensor for the real-time monitoring of tumor

regression. Sci. Adv. 2022; 8:eabn6550. doi:
10.1126/sciadv.abn6550. [PMC free article]

[PubMed] [CrossRef] [Google Scholar]

17.

Warnat-Herresthal S, et al. Swarm learning for

decentralized and confidential clinical machine
learning. Nature. 2021;594:265

270. doi:

10.1038/s41586-021-03583-3. [PMC free
article] [PubMed] [CrossRef] [Google Scholar

18.

18.

Lipson, S.M., Gordon, R.E., Ozen, F.S.,

Karthikeyan, L., Stotzky, G. Effect of cranberry

and grape juices on tightjunction function and
structural integrity among rotavirus-infected

money

kidney

epithelial

cell

culture

monolayers. Food Environ. Virol. 3, 2011; 46-

54.




References

Harrer S, et al. Artificial intelligence for clinical trial design. Trends Pharmacol. Sci. 2019; 40:577–591. doi: 10.1016/j.tips. 2019.05.005. [PubMed] [CrossRef] [Google Scholar].

Li BT, et al. Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition. Nat. Med. 2022; 28:620–626. doi: 10.1038/s41591-022-01775-6. [PubMed] [CrossRef] [Google Scholar]

Dagenais S, et al. Use of real-world evidence to drive drug development strategy and inform clinical trial design. Clin. Pharmacol. Ther. 2022; 111:77–89. doi: 10.1002/ cpt.2480. [PMC free article]

Liu R, et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature. 2021; 592:629–633.

Ithapu VK, et al. Imaging-based enrichment criteria using deep learning algorithms for efficient clinical trials in mild cognitive impairment. Alzheimers Dement. 2015; 11:1489–1499. doi: 10.1016/j.jalz. 2015.01.10. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Ezzati A, et al. Machine learning predictive models can improve efficacy of clinical trials for Alzheimer’s disease. J. Alzheimers Dis. 2020; 74:55–63. doi: 10.3233/JAD-190822. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Mohan A, et al. A machine-learning derived Huntington’s disease progression model: insights for clinical trial design. Mov.

de Jong J, et al. Towards realizing the vision of precision medicine: AI based prediction of clinical drug response. Brain. 2021; 144:1738–1750. doi: 10.1093/brain/awab-108. [PMC free article] [PubMed] [CrossRef] [Google Scholar].

Hassanzadeh H, et al. Matching patients to clinical trials using semantically enriched.

Alexander M, et al. Evaluation of an artificial intelligence clinical trial matching system in Australian lung cancer patients. JAMIA.

Haddad T, et al. Accuracy of an artificial intelligence system for cancer clinical trial eligibility screening: retrospective Pilot Study. JMIR Med. Inform. 2021;9:e27767.

Beck JT, et al. Artificial intelligence tool for optimizing eligibility screening for clinical trials in a large community cancer center. JCO Clin. Cancer Inform. 2020; 4:50–59. doi: 10.1200/CCI.19.00079. [PubMed] [CrossRef] [Google Scholar]

Kim J, et al. Review of the performance metrics for natural language systems for clinical trials matching. Stud. Health Technol. Inform. 2022; 290:641–644. [PubMed] [Google Scholar]

Unlearn works with pharma sponsors, biotech companies, and academic institutions. https://www.businesswire .com/news/home/20220419005354/en

European Medicines Agency releases for public consultation its draft policy on the publication and access to clinical-trial.

Abramson A, et al. A flexible electronic strain sensor for the real-time monitoring of tumor regression. Sci. Adv. 2022; 8:eabn6550. doi: 10.1126/sciadv.abn6550. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Warnat-Herresthal S, et al. Swarm learning for decentralized and confidential clinical machine learning. Nature. 2021;594:265–270. doi: 10.1038/s41586-021-03583-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar

Lipson, S.M., Gordon, R.E., Ozen, F.S., Karthikeyan, L., Stotzky, G. Effect of cranberry and grape juices on tightjunction function and structural integrity among rotavirus-infected money kidney epithelial cell culture monolayers. Food Environ. Virol. 3, 2011; 46-54.